Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles

Area of Science:

• Clinical immunology
• Allergology
• Pharmaceutical regulatory affairs

Background:

• Harmonization of efficacy and safety outcome measures for allergen immunotherapy (AIT) trials has progressed, yet challenges persist.
• Discrepancies exist between professional medical society recommendations and regulatory agency requirements for AIT trials.
• Current AIT product approval criteria by regulatory authorities necessitate updated guidance for trial design.

Purpose of the Study:

• To review published recommendations and current clinical trial data for AIT.
• To provide updated considerations for conducting phase 3 AIT trials.
• To identify areas for common ground among stakeholders in AIT trial design.

Main Methods:

• Review of published recommendations for AIT trials.
• Analysis of current data from recent clinical trials.
• Examination of regulatory authority criteria for AIT product approval.

Main Results:

• Discussion of outcome measures and trial designs for pediatric and asthma indications in AIT.
• Analysis of trial designs for perennial allergic rhinoconjunctivitis.
• Emphasis on the need for harmonized safety reporting in AIT trials.

Conclusions:

• Updated considerations for phase 3 AIT trial design are presented.
• Further efforts are needed to align recommendations from medical societies and government agencies.
• Harmonization of safety reporting is crucial for future AIT trial development.